AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B12
Description: 1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone (or corticosteroid equivalent)
Description: 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
Study NCT00806819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Study NCT04245683 — intervention group
Intervention type: PROCEDURE
Intervention: Bowel/rectal resection
Description: surgical removal of the portion of the rectum where the tumor was originally identified
Study NCT04245683 — intervention group
Intervention type: OTHER
Intervention: non-operative follow up
Description: patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
Study NCT00684541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program
Description: The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence.
Study NCT00684541 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Interpretation Control Condition
Description: Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
Study NCT04664699 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Plethymographic Variability Index
Description: All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume
Study NCT04664699 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Monitoring
Description: All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
Study NCT03103477 — intervention group
Intervention type: OTHER
Intervention: Urine stability
Description: This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
Study NCT00282308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied in single-use vials.
Study NCT00282308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT00282308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00282308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. albicans
Description: Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. albicans
Description: Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid adsorbed booster vaccine
Description: Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid adsorbed booster vaccine
Description: Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole limpet hemocyanin
Description: Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
Study NCT00282308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin
Description: Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
Study NCT02884713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Study NCT02884713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Study NCT02884713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Study NCT04079140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
Study NCT04079140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Study NCT02564835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
Study NCT02564835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: 6.25mg/kg bodyweight over 2h infusion
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Defibrotide
Description: 6.25mg/kg bodyweight over 2h infusion
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Description: (0.9% sodium chloride) infusion over 2h infusion
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (0.9% sodium chloride)
Description: (0.9% sodium chloride) infusion over 2h infusion
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: bolus infusion of 2ng/kg bodyweight lps
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide
Description: bolus infusion of 2ng/kg bodyweight lps
Study NCT02876601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (0.9% sodium chloride bolus)
Description: (0.9% sodium chloride) bolus infusion
Study NCT04371458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative providone-iodine lavage
Description: Intraoperative providone-iodine lavage during resection
Study NCT04234412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood stem cell implantation for osteoarthritis treatment
Description: The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface.
Study NCT01254760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, investigational
Description: Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
Study NCT01254760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, commercial
Description: Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
Study NCT00811486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone and conivaptan
Description: Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
Study NCT02983929 — intervention group
Intervention type: PROCEDURE
Intervention: Rehabilitation after total knee arthroplasty
Description: All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
Study NCT00692263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram and tramadol
Description: 10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
Study NCT00692263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
Study NCT00692263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo and tramadol
Description: 9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
Study NCT00974480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin (Rejuva-A)
Description: Tretinoin 0.025% cream.
Study NCT02329418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explaining withholding and withdrawing life-sustaining therapies along with a written document
Description: The document describes the law and the role of family members and medical team in the decision.
Study NCT02329418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explaining withholding and withdrawing life-sustaining therapies following standard procedure
Study NCT02302014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
Study NCT01901913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-bolus calculator for pre-meal bolus
Study NCT01901913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No MD-bolus calculator for pre-meal bolus
Study NCT03311698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition-sensitive intervention
Description: Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
Study NCT00202878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Description: Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Study NCT00202878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Study NCT00202878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for simvastatin 40 mg
Description: one or two tablets orally daily
Study NCT00202878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for simvastatin 40 mg
Description: one or two tablets orally daily
Study NCT00384046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
Study NCT00384046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patch, placebo, patch changed every 3-4 days, 24 weeks
Study NCT01341613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioviva™ supplement capsule
Description: Twice per day (BID), 9 weeks
Study NCT01341613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Twice per day (BID), 9 weeks
Study NCT02923297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: blood sampling for determine and compare the expression patterns of GALIG gene
Study NCT00309491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Description: 2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
Study NCT00309491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Aminoglutethimide
Description: 2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily
Study NCT01680042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin paste
Study NCT01680042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02644421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149
Study NCT02644421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02644421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02506348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02506348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Study NCT03959267 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Genetic Counseling
Description: A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
Study NCT00939393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FESS instruments with or without balloon treatment
Description: Intervention with metal instruments with or without balloon treatment
Study NCT00939393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sinuplasty
Description: Balloon dilatation of sinuses
Study NCT01965678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Study NCT02722083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (BAY X002134)
Description: 4 mg tablet, single dose, orally
Study NCT02722083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet, single dose, orally
Study NCT02248246 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Harmonic ACE®+7 Shears
Description: Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)
Study NCT01671319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + cyclophosphamide + pegfilgrastim
Description: docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
Study NCT03083873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
Study NCT03083873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145-S1
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
Study NCT02805829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + NK cells
Description: NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
Study NCT01399372 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
Study NCT01399372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.